Class Action Lawsuit Filed Against Anavex Life Sciences Corp.

Investors allege misleading information regarding clinical trial success led to significant stock price drops.

A class action lawsuit has been filed against Anavex Life Sciences Corp. for allegedly misleading investors about the success of its clinical trials.
The lawsuit covers all persons and entities who purchased or acquired Anavex securities between February 1, 2022, and January 1, 2024.
Anavex's stock price fell significantly following announcements of disappointing trial results for its drug blarcamesine.
Law firms are encouraging affected investors to join the class action lawsuit before the May 13, 2024 deadline.
Multiple law firms have announced their involvement in representing investors in the lawsuit against Anavex.